The stock of Abzena PLC (LON:ABZA) hit a new 52-week low and has GBX 26.66 target or 14.00% below today’s GBX 31.00 share price. The 8 months bearish chart indicates high risk for the GBX 43.84M company. The 1-year low was reported on Nov, 16 by Barchart.com. If the GBX 26.66 price target is reached, the company will be worth GBX 6.14M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. The stock decreased 6.06% or GBX 2 on November 16, hitting GBX 31. About 16,000 shares traded hands or 238.70% up from the average. Abzena PLC (LON:ABZA) has declined 34.00% since April 15, 2016 and is downtrending. It has underperformed by 38.69% the S&P500.
Abzena PLC (LON:ABZA) Ratings Coverage
Out of 2 analysts covering Abzena Plc (LON:ABZA), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Abzena Plc has been the topic of 8 analyst reports since September 14, 2015 according to StockzIntelligence Inc. N+1 Singer maintained the shares of ABZA in a report on Friday, October 21 with “Corporate” rating. The stock of Abzena PLC (LON:ABZA) earned “Corporate” rating by N+1 Singer on Thursday, January 7. N+1 Singer maintained the stock with “Buy” rating in Monday, October 12 report. N+1 Singer maintained the stock with “Buy” rating in Monday, September 21 report. The firm has “Buy” rating given on Monday, September 14 by N+1 Singer. The rating was maintained by N+1 Singer on Tuesday, November 24 with “Corporate”. The company was maintained on Monday, January 25 by N+1 Singer.
More important recent Abzena PLC (LON:ABZA) news were published by: Businesswire.com which released: “Abzena plc: Placing to Raise £20 Million and Acquisition” on November 24, 2015, also Businesswire.com published article titled: “Abzena Plc: PacificGMP Makes Two Senior Appointments”, Businesswire.com published: “Abzena plc full year results: revenues up 74%, strong outlook within growing …” on June 14, 2016. More interesting news about Abzena PLC (LON:ABZA) was released by: Businesswire.com and their article: “Abzena plc: Adheron Therapeutics is Acquired by Roche for Its Therapeutic Antibody” with publication date: October 09, 2015.
Abzena plc is a life sciences company. The company has a market cap of 43.84 million GBP. The Firm provides technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It currently has negative earnings. It has a global customer base which includes approximately 20 biopharmaceutical companies, as well as large and small biotech companies and academic groups.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.